Literature DB >> 35121936

How to kill Treg cells for immunotherapy.

Gavin I Ellis1, James L Riley2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 35121936     DOI： 10.1038/s43018-020-00155-8

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


× No keyword cloud information.
  2 in total

1.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Authors:  S Onizuka; I Tawara; J Shimizu; S Sakaguchi; T Fujita; E Nakayama
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

2.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422
  2 in total
  3 in total

1.  PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.

Authors:  Jianhua Liu; Hao Chen; Guibin Qiao; Jia-Tao Zhang; Shuaitong Zhang; Changbin Zhu; Yu Chen; Jiming Tang; Weiwei Li; Siyun Wang; Hongxia Tian; Zhihong Chen; Dong Ma; Jie Tian; Yi-Long Wu
Journal:  Cancer Immunol Immunother       Date:  2022-09-19       Impact factor: 6.630

Review 2.  Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.

Authors:  Evangelos Koustas; Eleni-Myrto Trifylli; Panagiotis Sarantis; Nikolaos Papadopoulos; Eleni Karapedi; Georgios Aloizos; Christos Damaskos; Nikolaos Garmpis; Anna Garmpi; Kostas A Papavassiliou; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

3.  Abnormally Expressed Ferroptosis-Associated FANCD2 in Mediating the Temozolomide Resistance and Immune Response in Glioblastoma.

Authors:  Liying Song; Jiali Wu; Hua Fu; Cuifang Wu; Xiaopei Tong; Mingyu Zhang
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.